At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 38 enrolled
Drug / intervention
Cefzil® 500 mg tablets +1 moredrug
Likely dose
Cefzil® 500 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of Cefprozil 500 mg Tablets Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Cefzil® 500 mg tablets and Cefprozil 500 mg Tablets for Healthy. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets (Teva Pharmaceuticals USA) with that of Cefzil® 500 mg tablets (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
Primary CompletionSep 2003
First PostedFeb 2009
TodayJul 2026
First PostedFeb 10, 2009
Enrollment StartSep 1, 2003
Primary CompletionSep 1, 2003
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago
Interventions
Cefzil® 500 mg tabletsdrug
1 x 500 mg, single-dose fasting
Cefprozil 500 mg Tabletsdrug
1 x 500 mg, single-dose fasting